Literature DB >> 11297036

The balance of concurrent aggregation and deaggregation processes in platelets is linked to differential occupancy of ADP receptor subtypes.

S Maayani1, T M Tagliente, T Schwarz, G Martinelli, R Martinez, L Shore-Lesserson.   

Abstract

Deaggregation, the partial reversal of the initial aggregation of platelets is observed following low, but not higher, micromolar ADP concentrations. This study tested the hypothesis that deaggregation results from a balance between concurrent, opposing, aggregation and deaggregation processes which are ADP (adenosine 5'-diphosphate) receptor occupancy-dependent. Aggregation of human platelet-rich plasma (PRP) prepared in r-hirudin was assayed in a 96-well plate reader over 20 min by measurement of the optical density (OD) at 580 nm. Aggregation and the time to reach peak aggregation were directly proportional to ADP receptor occupancy. The magnitude and time course of the response to ADP were comparable to those previously reported with standard aggregometry. The rate constant of platelet deaggregation, as assessed by a four-compartment kinetic model, was inversely proportional to agonist concentration. The ratio of the rate constants of aggregation and deaggregation was receptor occupancy-dependent and directly proportional to aggregation. Consequently, platelet aggregation was proportional, and deaggregation inversely proportional, to ADP receptor occupancy. We propose that the response of PRP to ADP and to 2-MeS-ADP (2-methylthioadenosine-diphosphate), in vitro, consists of at least two active, concurrent processes, aggregation and deaggregation. Incremental occupancy of the P2T ADP receptor subtype attenuates deaggregation and governs the balance between these two processes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11297036     DOI: 10.1080/09537100020032846

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  2 in total

1.  Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk.

Authors:  Douglas Moeckel; Soon Soeg Jeong; Xiaofeng Sun; M Johan Broekman; Annie Nguyen; Joan H F Drosopoulos; Aaron J Marcus; Simon C Robson; Ridong Chen; Dana Abendschein
Journal:  Sci Transl Med       Date:  2014-08-06       Impact factor: 17.956

2.  RGD-independent binding of Russell's Viper venom Kunitz-type protease inhibitors to platelet GPIIb/IIIa receptor.

Authors:  Bhargab Kalita; Sumita Dutta; Ashis K Mukherjee
Journal:  Sci Rep       Date:  2019-06-05       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.